CD274 and neoplasm: In 2016, the OAK study with atezolizumab and the Keynote 010 study with pembrolizumab presented the first data involving correlations between clinical outcomes (response and survival) and programmed death-ligand 1 (PD-L1) expression in tumor tissue samples [1,2,3,4].